Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
DSGN - Design Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.50
DETAILS
HIGH:
$21.00
LOW:
$14.00
MEDIAN:
$17.50
CONSENSUS:
$17.50
UPSIDE:
59.53%
Stock News
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026.
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and Securities of $222.8 Million at Quarter-End Provide Runway to Support Ongoing Clinical Execution CARLSBAD, Calif.
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong
Design Therapeutics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present at the following upcoming investor conferences: Oppenheimer 36 th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 1:20 p.m.
Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $10.13, but opened at $10.48. Design Therapeutics shares last traded at $10.10, with a volume of 9,741 shares changing hands. Analyst Ratings Changes DSGN has been the topic of several analyst
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company.
Price Targets
Design Therapeutics price target raised to $21 from $18 at Oppenheimer
$21.00
(was $13.30)
Oppenheimer
Design Therapeutics price target raised to $20 from $12 at Piper Sandler
$20.00
(was $15.24)
Piper Sandler
Design Therapeutics initiated with an Outperform at Oppenheimer
$18.00
(was $8.82)
Oppenheimer
Design Therapeutics initiated with a Buy at Craig-Hallum
$15.00
(was $8.94)
Adam Vogel
·
Craig-Hallum
Design Therapeutics upgraded to Outperform from Market Perform at Leerink
$14.00
(was $8.94)
Joseph Schwartz
·
Leerink Partners
Piper Sandler Upgrades Design Therapeutics Inc (DSGN) to Overweight
$12.00
(was $3.65)
Yasmeen Rahimi
·
Piper Sandler
Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments
$7.00
(was $2.17)
Leonid Timashev
·
RBC Capital
Design Therapeutics' DT-216 phase 1 data looks promising, says Piper Sandler
$42.00
(was $12.69)
Yasmeen Rahimi
·
Piper Sandler
RBC Capital Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $30
$30.00
(was $11.94)
RBC Capital
Design Therapeutics Stock (DSGN): $10 Price Target From Goldman Sachs
$10.00
(was $13.98)
Madhu Kumar
·
Goldman Sachs